RT Journal Article
SR Electronic
T1 Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.17.24314397
DO 10.1101/2024.10.17.24314397
A1 Hao, Tianxiao
A1 Ryan, Gerard E.
A1 Lydeamore, Michael J.
A1 Cromer, Deborah
A1 Wood, James
A1 McVernon, Jodie
A1 McCaw, James M.
A1 Shearer, Freya M.
A1 Golding, Nick
YR 2024
UL http://medrxiv.org/content/early/2024/10/18/2024.10.17.24314397.abstract
AB Quantifying the extent to which previous infections and vaccinations confer protection against future infection or disease outcomes is critical to managing the transmission and consequences of infectious diseases.We present a general statistical model for predicting the strength of protection conferred by different immunising exposures (numbers, types, and variants of both vaccines and infections), against multiple outcomes of interest, whilst accounting for immune waning. We predict immune protection against key clinical outcomes: developing symptoms, hospitalisation, and death. We also predict transmission-related outcomes: acquisition of infection and onward transmission in breakthrough infections. These enable quantification of the impact of immunity on population-level transmission dynamics. Our model calibrates the level of immune protection, drawing on both population-level data, such as vaccine effectiveness estimates, and neutralising antibody levels as a correlate of protection. This enables the model to learn realised immunity levels beyond those which can be predicted by antibody kinetics or other correlates alone.We demonstrate an application of the model for SARS-CoV-2, and predict the individual-level protective effectiveness conferred by natural infections with the Delta and the Omicron B.1.1.529 variants, and by the BioNTech-Pfizer (BNT162b2), Oxford-AstraZeneca (ChAdOx1), and 3rd-dose mRNA booster vaccines, against outcomes for both Delta and Omicron. We also demonstrate a use case of the model in late 2021 during the emergence of Omicron, showing how the model can be rapidly updated with emerging epidemiological data on multiple variants in the same population, to infer key immunogenicity and intrinsic transmissibility characteristics of the new variant, before these can be directly observed via vaccine effectiveness data.This model provided timely inference on rapidly evolving epidemic situations of significant concern during the early stages of the COVID-19 pandemic. The general nature of the model enables it to be used to support management of a range of infectious diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work received funding from the Department of Health and Aged Care Australia and the SPECTRUM Centre of Research Excellence funded by the Australian National Health and Medical Research Council (NHMRC; grant no. 1170960). T. Hao was supported by NHMRC Ideas Grant (grant no. 2019093), F. M. Shearer was supported by an NHMRC Investigator Grant (no. 2010051), D. Cromer was supported by an NHMRC Investigator Grant (no. 1173528).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at the following publications: https://www.medrxiv.org/content/10.1101/2021.09.28.21264260v2 https://www.nejm.org/doi/10.1056/NEJMoa2119451 https://www.medrxiv.org/content/10.1101/2021.09.15.21263583v2 https://www.nature.com/articles/s41591-021-01548-7 https://www.nature.com/articles/s41591-021-01377-8I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data used in this study are available at published sources: https://www.medrxiv.org/content/10.1101/2021.09.28.21264260v2 https://www.nejm.org/doi/10.1056/NEJMoa2119451 https://www.medrxiv.org/content/10.1101/2021.09.15.21263583v2 https://www.nature.com/articles/s41591-021-01548-7 https://www.nature.com/articles/s41591-021-01377-8